Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

• Results Overview

  Abrocitinib (oral medication) worked better than dupilumab (injection) at reducing itch and eczema symptoms in adults with moderate-to-severe eczema, particularly in the early weeks of treatment.

• Study Summary

  Num Participants:

  727

  Study Type:

  Rct

  Control Group:

  Subcutaneous Dupilumab 300 Mg Every 2 Weeks

  Efficacy End Points Treatment:

  {'PP-NRS4': 48, 'EASI-90': 29}

  Efficacy End Points Control:

  {'PP-NRS4': 26, 'EASI-90': 15}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected